TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30558672
Drug: Subcutaneous spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous spacer injection
Study: 19808950
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg per day
Study: 17484092
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg per day
Study: 10023697
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body/day for 7 days
Study: 10023697
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body/day for 5 days
Study: 10023697
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body/day for 10 days
Study: 6541929
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxazolam with 0.55 g/kg alcohol
Study: 6541929
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oxazolam with 0.55 g/kg alcohol
Study: 6541929
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oxazolam with 0.83 g/kg alcohol
Study: 6541929
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 0.55 g/kg alcohol
Study: 27449412
Drug: GCSB-5 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSB-5 600 mg, bid for 12 weeks
Study: 22482863
Drug: LI-guided pre-emptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI-guided pre-emptive therapy (group 3, n = 71)
Study: 22482863
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group 2, n = 142)
Study: 1861917
Drug: Sulfisoxazole 75
Normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole 75 mg/kg per day for 6 months
Study: 26765633
Drug: 2 g·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g·d of DHA
Study: 26765633
Drug: 4 g·d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g·d of DHA
Study: 23772853
Drug: Perampanel 2-12
Normalized name: perampanel 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 2-12 mg
Study: 20439606
Drug: Dual-boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-boosted protease inhibitor combinations
Study: 10596413
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose treatment with surfactant (Curosurf)
Study: 10596413
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose treatment with surfactant (Curosurf)
Study: 6962738
Drug: Cigarette averaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette averaging .64 mg nicotine (P2)
Study: 6962738
Drug: Cigarette averaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette averaging .38 mg nicotine (P3)
Study: 6962738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group switched to another brand within ± .1 mg of their usual brand (P2)
Study: 6962738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group switched to another brand within ± .1 mg of their usual brand (P3)
Study: 27404053
Drug: MPFF 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 500 mg
Study: 28804864
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS)
Study: 24012456
Drug: < 3
Normalized name: Ryoncil Kit Patient Weight 25 - < 37.5 KG
Approvals — FDA: no, EMA: no, PMDA: no
Description: < 3 CTC per 7.5 mL blood and KRAS wild-type tumors
Study: 21345850
Drug: More intense
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intense therapy (low-dose hydrochlorothiazide and low-dose felodipine)
Study: 21345850
Drug: Less-intense therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-intense therapy (low-dose hydrochlorothiazide and placebo)
Study: 10211032
Drug: Ropivacaine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 75 mg in 0.9% saline 60 ml
Study: 25827960
Drug: 10mg/m(2)/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/m(2)/day of oral hydrocortisone in three divided doses
Study: 24640651
Drug: Coordination gymnastics
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coordination gymnastics combined with magnetic therapy and iodine-bromine baths
Study: 16322489
Drug: Trials with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials with a treatment window >6 hours
Study: 16322489
Drug: Trials with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trials with a treatment window <=6 hours
Study: 14613518
Drug: Omacor 1
Normalized name: Omacor 1 GM Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 1 g, o.d.
Study: 8822290
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE) for 5 days at 30 mg/kg/day in 2 divided doses
Study: 8822290
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE) for 10 days at 30 mg/kg/day in 2 divided doses
Study: 8822290
Drug: Amoxicillin/clavulanate (AMX/CL)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (AMX/CL) for 10 days at 40 mg/kg/day in 3 divided doses
Study: 6523650
Drug: Cefuroxime (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (antibiotic group)
Study: 22508376
Drug: Carbidopa 75
Normalized name: carbidopa 18.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa 75 mg/day
Study: 2163805
Drug: BAY m1099
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY m1099 (50 mg thrice daily)
Study: 2024740
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 10 mg
Study: 22395731
Drug: Dopamine antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine antagonist (haloperidol)
Study: 9141982
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid (fluticasone) 200 micrograms when needed (up to 400 micrograms/d) + 1-2 tablets of terfenadine daily (max 120 mg/d)
Study: 9141982
Drug: Antihistamine (terfenadine)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (terfenadine) 1 tablet of 60 mg when needed (max 120 mg/d) + 200-400 micrograms/d of fluticasone nasal spray if needed
Study: 3099611
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nasal spray for 6 weeks together with terfenadine for 1 week
Study: 28592016
Drug: Oseltamivir (30‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (30‐75 mg, twice daily for 5 days)
Study: 18182196
Drug: Infusion pump
Normalized name: Infusion Pump 50cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion pump with 0.5% bupivacaine
Study: 18182196
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block combined with an infusion pump containing 0.9% saline solution
Study: 18182196
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block combined with an infusion pump containing 0.5% bupivacaine
Study: 18182196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Infusion pump with saline solution)
Study: 10589439
Drug: Andrographis paniculata
Normalized name: Andrographis paniculata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andrographis paniculata dried extract (1200 mg/day)
Study: 8636343
Drug: Fludrocortisone 0.1
Normalized name: fludrocortisone 0.1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.1 mg
Study: 8636343
Drug: Fludrocortisone 0
Normalized name: fludrocortisone 0.001 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0 mg (placebo)
Study: 6168840
Drug: Pindolol (10‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10‐45 mg/day)
Study: 31033396
Drug: Ad exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad exposure frequency (viewing the ad once, twice, or four times)
Study: 19180894
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied to one-half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Study: 19180894
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied to the other half of the face, 2-times-per-week for 16 weeks after photodynamic therapy.
Study: 13680283
Drug: 3x2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x2 mg budesonide
Study: 13680283
Drug: 3x6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x6 mg budesonide
Study: 11679989
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, and 1 x 10(6) KIU before reperfusion; n = 10)
Study: 11679989
Drug: Regular-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular-dose aprotinin (2 x 10(6) KIU at induction and continuous infusion of 0.5 x 10(6) KIU/h; n = 8)
Study: 8003847
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (n = 939)
Study: 8003847
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (n = 939) among women who had never used oestrogen replacement therapy (n = 1427)
Study: 8003847
Drug: Non-users (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users (n = 2283) among women who had never used oestrogen replacement therapy (n = 1427)
Study: 8003847
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (n = 939) among premenopausal women (n = 387)
Study: 3341390
Drug: Indapamide 1
Normalized name: indapamide 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1 mg per day
Study: 3341390
Drug: Indapamide 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 5.0 mg per day
Study: 17184605
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing Lactobacillus casei and Streptococcus thermophilus (0.5 l/day) for 6 weeks
Study: 17184605
Drug: Standard cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cow's milk (0.5 l/day) for 12 weeks
Study: 15004973
Drug: Zi-Factor (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zi-Factor (250 mg azithromycin capsules)
Study: 15004973
Drug: Reference-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference-drug
Study: 6377153
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g oral dose of metronidazole (Flagyl)
Study: 11257348
Drug: DTPa-HBV-IPV/Hib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-HBV-IPV/Hib combination vaccine
Study: 18611978
Drug: Transdermal E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal E(2) supplementation
Study: 16488678
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration 4 hours postoperatively, daily for 4 weeks
Study: 16488678
Drug: No clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No clopidogrel administration
Study: 26903002
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration
Study: 11023194
Drug: Intratumoral interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral interferon-gamma (IFN-gamma) retroviral vector, 10(7) plaque-forming units/mL administered at 0.3, 0.5, and 1.0 mL per cohort of patients, five daily injections every 2 weeks.
Study: 11023194
Drug: Intratumoral interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral interferon-gamma (IFN-gamma) retroviral vector, multiple injections.
Study: 9376465
Drug: Metamizol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (1 g/100 ml NaCl 0.9% intravenously over 15 min) plus diclofenac (100 mg suppository) administered before induction and repeated at 6 h and 12 h.
Study: 29580238
Drug: Traditional facility-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional facility-based treatment for SAM
Study: 12468439
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone propionate (500 microg twice a day)
Study: 12468439
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone propionate (100 microg twice a day)
Study: 8750370
Drug: Intravenous TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TCA (2 mg as phosphate ester)
Study: 8750370
Drug: Oral TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TCA (5 mg)
Study: 8750370
Drug: Inhaled TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled TCA (2 mg)
Study: 7408529
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mefenamic acid three times daily
Study: 31987558
Drug: No stretch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stretch, 30 s stretch, multiple (4×) 30 s stretch, and dynamic stretch (treatment conditions)
Study: 17580512
Drug: Orthotropic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthotropic treatment (growth guidance)
Study: 15767953
Drug: Morphine aerosols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine aerosols (4 mls of morphine sulphate nebulised 4 hourly)
Study: 15767953
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline aerosols (4 mls of normal saline nebulised 4 hourly)
Study: 30348586
Drug: teriflunomide 14
Normalized name: teriflunomide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriflunomide 14 mg
Study: 22768848
Drug: Discharge planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discharge planning therapies primarily within the home environment
Study: 29097974
Drug: Information processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information processing strategy training (PRPP System of Intervention and 4QM), 50 minutes per session, twice a week for 6 weeks
Study: 29097974
Drug: Traditional intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional intervention, twice a week for 6 weeks
Study: 24330156
Drug: NF3 (two-herb
Approvals — FDA: no, EMA: no, PMDA: no
Description: NF3 (two-herb traditional Chinese medicine)
Study: 19226381
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg/day for 52 weeks
Study: 19226381
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg/day for additional 68-92 weeks
Study: 19226381
Drug: Entecavir treatment
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir treatment with annual liver biopsies
Study: 11726010
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with diuretics or beta-blockers (Group 1)
Study: 11726010
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with calcium channel blockers or angiotensin-converting enzyme inhibitors (Group 2)
Study: 9164833
Drug: SCT+Ca (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT+Ca (100 IU/day I.M. of SCT plus 1200 mg of elemental Ca for 10 days each month)
Study: 9164833
Drug: Ca (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca (1200 mg of elemental Ca for 10 days each month)
Study: 3609189
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (2 X 4 mg)
Study: 3609189
Drug: Subcutaneous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adrenaline (2 X 0.5 mg)
Study: 25722360
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) for 6 weeks, weekly sessions.
Study: 20516379
Drug: cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (100 to 200 mg/d)
Study: 20516379
Drug: aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (81 to 100 mg/d)
Study: 19264451
Drug: Levetiracetam XR
Normalized name: levetiracetam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam XR with food (1000mg single dose)
Study: 15723428
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of nizatidine 300 mg capsules
Study: 15723428
Drug: Innovator formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator formulation of nizatidine 300 mg capsules
Study: 3197710
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both formulations
Study: 23672224
Drug: Western drugs
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western drugs
Study: 1752926
Drug: Spontaneous urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous urinary luteinizing hormone (LH) surge
Study: 7133974
Drug: Pirprofen 200
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 200 mg
Study: 11180025
Drug: Mizolastine 5
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 5 mg
Study: 11180025
Drug: Mizolastine 15
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 15 mg
Study: 7875184
Drug: Mizolastine 45
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 45 mg
Study: 28809990
Drug: Desoximetasone 0.05%
Normalized name: DESOXIMETASONE 0.05% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone 0.05% spray
Study: 28809990
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator control (clobetasol spray)
Study: 12490789
Drug: Full-dose CsA
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose CsA (microemulsion) plus fixed-dose SRL (2 mg/day; group A, n=97)
Study: 9661093
Drug: Right unilateral
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right unilateral electroconvulsive therapy (ECT)
Study: 3745846
Drug: metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10 mg q.i.d.
Study: 18207124
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin + topical prednisolone phosphate
Study: 18207124
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin + placebo
Study: 15381937
Drug: 5-Fluorouracil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil 500 mg/m² plus Epirubicin 75 mg/m² and Cyclophosphamide 500 mg/m² (FEC)
Study: 11416804
Drug: Kinestherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinestherapy and inhaled bronchodilator drugs (salbutamol and/or ipratropium bromide) with a boreal nebulizer, bronchial hygiene, breathing exercises on a Bodyguard Ergometer 990, treated three times per week for twelve weeks.
Study: 3790399
Drug: Ethanol consumption
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol consumption (66 g per day)
Study: 26653612
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR 60 mg once daily (FIRST group)
Study: 26653612
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR 60 mg once daily (SWITCH group)
Study: 26653612
Drug: Gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide MR 60 mg once daily
Study: 25439972
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT), 8 sessions of 2 hours each
Study: 2898244
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) (2 mg/day)
Study: 2898244
Drug: Gold sodium
Normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold sodium thiomalate (GST) (50 mg/week)
Study: 29659969
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg aspartame/d
Study: 29659969
Drug: 1050 mg
Normalized name: guaifenesin 1050 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1050 mg aspartame/d
Study: 29659969
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg aspartame/d (control group)
Study: 26148063
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis before skin incision